Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT
Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
Cytokinetics Inc (CYTK)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 3,073,853 | $123,538,152 | +23% | 4% |
| 2. | 2,700,000 | $108,513,000 | +343% | 1.63% | |
| 3. | Vestal Point Capital Ryan Wilder | 2,590,531 | $104,113,441 | +11% | 7.43% |
| 4. | Polar Capital Brian Ashford-Russell And Tim Woolley | 2,455,737 | $98,696,070 | +12% | 0.6% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 2,028,792 | $81,537,153 | -6% | 0.1% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.57 | 6,000 | $51,426.60 | 6,250 | 2019-11-19 | Filing | |
| $9.52 | 8,506 | $80,934.59 | 499,312 | 2019-12-11 | Filing | |
| $9.52 | 49,804 | $473,885.06 | 2,861,622 | 2019-12-11 | Filing | |
| $9.52 | 60,103 | $571,880.05 | 3,617,776 | 2019-12-11 | Filing | |
| $9.40 | 15,030 | $141,282.00 | 490,806 | 2019-12-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $33.76 | 2,000 | $67,520.00 | 140,610 | 2025-07-08 | Filing | |
| $33.55 | 5,000 | $167,750.00 | 398,108 | 2025-07-01 | Filing | |
| $32.91 | 2,000 | $65,820.00 | 140,610 | 2025-06-17 | Filing | |
| $33.80 | 5,000 | $169,000.00 | 403,108 | 2025-06-16 | Filing | |
| $32.10 | 3,636 | $116,715.60 | 29,658 | 2025-06-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 407,037 | $13,448,502 | 0.33% | |
| 2. | 64,000 | $68,064 | 0.01% | |
| 3. | 785 | $25,936 | 0% | |
| 4. | 476 | $15,727 | 0.01% | |
| 5. | 381 | $12 | 0% |
News See All
13 Best Pharma Stocks to Buy According to Wall Street Analysts
On June 24, Jared Holz, Mizuho's healthcare strategist, appeared on CNBC's 'Fast Money' to talk about competition in the obesity drug space.
Cytokinetics Presents Positive Aficamten Data for Obstructive HCM at European Heart Failure Congress
Cytokinetics Incorporated (NASDAQ:CYTK) is one of the most active stocks to buy according to analysts.
11 Best Most Active Stocks To Buy According to Analysts
The Co-Chief Investment Strategist at John Hancock Investment Management, Emily Roland, believes that we're in a period of serious disinflation.
Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan
Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the 13 Biotech Stocks with Huge Upside Potential.
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to Cytokinetics' First Quarter 2025 Conference Call. At this time, I would like to inform you that this call is being recorded.
10 Best High Short Interest Stocks to Buy Now
Aditya Bhave, BofA Securities head of US Economics, joined 'Power Lunch' on CNBC on April 17 to talk about whether tariffs are ultimately inflationary, disinflationary, or deflationary.
10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
12 Most Promising Biotech Stocks According to Wall Street Analysts
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
Billionaire Hedge Funds
